



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/9334/2025

European Medicines Agency decision P/0002/2025

of 28 January 2025

on the agreement of a paediatric investigation plan and on the granting of a deferral for 2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione (KL1333), (EMA-003618-PIP01-24) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0002/2025

of 28 January 2025

on the agreement of a paediatric investigation plan and on the granting of a deferral for 2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione (KL1333), (EMA-003618-PIP01-24) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Abliva AB on 25 March 2024 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 13 December 2024, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for 2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione (KL1333), film-coated tablet, age-appropriate oral liquid dosage form, oral use, gastric use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for 2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione (KL1333), film-coated tablet, age-appropriate oral liquid dosage form, oral use, gastric use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Abliva AB, Medicion Village, SE-223 81 – Lund, Sweden.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/434851/2024

Amsterdam, 13 December 2024

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMA-003618-PIP01-24

Scope of the application

Active substance(s):

2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione (KL1333)

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of primary mitochondrial disease

Pharmaceutical form(s):

Film-coated tablet

Age-appropriate oral liquid dosage form

Route(s) of administration:

Oral use

Gastric use

Name/corporate name of the PIP applicant:

Abliva AB

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Abliva AB submitted for agreement to the European Medicines Agency on 25 March 2024 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 29 April 2024.

Supplementary information was provided by the applicant on 9 September 2024. The applicant proposed modifications to the paediatric investigation plan.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation.

The Paediatric Committee members of Liechtenstein and Norway agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Treatment of primary mitochondrial disease

2.1.1. Indication(s) targeted by the PIP

Treatment of primary mitochondrial disease (PMD)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Age-appropriate oral liquid dosage form

2.1.4. Measures

Area	Description
Quality-related studies	<p>Study 1</p> <p>Development of film-coated tablets suitable for the paediatric population from 6 years to less than 18 years of age.</p> <p>Study 2</p> <p>Development of an age-appropriate oral liquid dosage form suitable for children younger than 6 years of age (and paediatric patients unable to swallow the film-coated tablets)</p>
Non-clinical studies	Not applicable
Clinical studies	<p>Study 3 (alternative design option)</p> <p>Single-arm, open-label trial to evaluate the pharmacokinetics, safety and clinical activity of 2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione (KL1333) in paediatric patients from birth to less than 18 years of age with primary mitochondrial disease.</p> <p>Study 4 (alternative design option)</p> <p>Randomised, double-blind, placebo-controlled or cross-over trial to evaluate the efficacy, safety and pharmacokinetics and of 2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione (KL1333) in paediatric patients from birth to less than 18 years of age with primary mitochondrial disease.</p>

Modelling and simulation analyses	Study 5 Use of PopPK analysis to predict initial paediatric doses to be used in the paediatric clinical studies and to subsequently confirm achievement of expected exposure.
Other studies	Study 6 Review of the Mitochondrial Research Patient Cohort database and other literature data (if available) to support the identification and the definition of patient populations with primary mitochondrial disease (PMD) for paediatric interventional clinical trial(s) of KL1333 and inform potential options for study endpoints.
Extrapolation plan	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By March 2034
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.